<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>0 | Seppälä Lab</title><link>https://www.seppalalab.org/publication-type/0/</link><atom:link href="https://www.seppalalab.org/publication-type/0/index.xml" rel="self" type="application/rss+xml"/><description>0</description><generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en</language><lastBuildDate>Sun, 01 Jan 2023 00:00:00 +0000</lastBuildDate><image><url>https://www.seppalalab.org/media/logo_hu_e3f0d28ad302f75b.png</url><title>0</title><link>https://www.seppalalab.org/publication-type/0/</link></image><item><title>Editorial: Identification, risk stratification, and optimized management for Lynch Syndrome</title><link>https://www.seppalalab.org/publication/bernstein-2023-editorial/</link><pubDate>Sun, 01 Jan 2023 00:00:00 +0000</pubDate><guid>https://www.seppalalab.org/publication/bernstein-2023-editorial/</guid><description/></item><item><title>The prognostic role of tumor budding and tumor-stroma ratio in pulmonary metastasis of colorectal carcinoma</title><link>https://www.seppalalab.org/publication/karjula-2023-the/</link><pubDate>Sun, 01 Jan 2023 00:00:00 +0000</pubDate><guid>https://www.seppalalab.org/publication/karjula-2023-the/</guid><description/></item><item><title>Response to Chambuso et al</title><link>https://www.seppalalab.org/publication/dominguez-valentin-2022-response/</link><pubDate>Sat, 01 Jan 2022 00:00:00 +0000</pubDate><guid>https://www.seppalalab.org/publication/dominguez-valentin-2022-response/</guid><description/></item><item><title>Solving for Chemotherapeutic Sensitivity: Adapting "Black Box" Methods to Study Patient-Derived Tumor Organoids</title><link>https://www.seppalalab.org/publication/seppala-2022-solving/</link><pubDate>Sat, 01 Jan 2022 00:00:00 +0000</pubDate><guid>https://www.seppalalab.org/publication/seppala-2022-solving/</guid><description/></item><item><title>Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum</title><link>https://www.seppalalab.org/publication/dominguez-valentin-2021-analysis/</link><pubDate>Fri, 01 Jan 2021 00:00:00 +0000</pubDate><guid>https://www.seppalalab.org/publication/dominguez-valentin-2021-analysis/</guid><description/></item><item><title>Towards evidence-based personalised precision medicine for Lynch syndrome</title><link>https://www.seppalalab.org/publication/moller-2021-towards/</link><pubDate>Fri, 01 Jan 2021 00:00:00 +0000</pubDate><guid>https://www.seppalalab.org/publication/moller-2021-towards/</guid><description/></item><item><title>Response to Tolva et al</title><link>https://www.seppalalab.org/publication/sampson-2020-response/</link><pubDate>Wed, 01 Jan 2020 00:00:00 +0000</pubDate><guid>https://www.seppalalab.org/publication/sampson-2020-response/</guid><description/></item><item><title>Towards Explaining International Differences in Health Care Performance: Results of the EuroHOPE Project</title><link>https://www.seppalalab.org/publication/hakkinen-2015-towards/</link><pubDate>Thu, 01 Jan 2015 00:00:00 +0000</pubDate><guid>https://www.seppalalab.org/publication/hakkinen-2015-towards/</guid><description/></item></channel></rss>